In 2023, Italy saw a slight increase of 0.95% in antiarrhythmic medicine sales, reaching 84.3 million Euros in 2024, confirming its leading position in Europe. Germany experienced a -3.96% decline, resulting in 55.8 million Euros. Spain, with a -5.17% drop, settled at 22.7 million Euros. Greece fell by -4.9% to 6.3 million Euros, while Ireland's 0.64% increase brought it to 3.2 million Euros. Estonia faced the sharpest decline at -8.97%, with sales reaching 0.5 million Euros.
Future trends to watch for:
- Increasing demand in Italy may continue based on current positive trends.
- Ongoing declines in Germany, Spain, Greece, and Estonia.
- Technological advances and new market entrants could reshape the market dynamics.
Top countries in Antiarrhythmic Medicine Sales by Country
| # | 6 Countries | Million Euros | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Italy | 84.3 | 2023 | +2.8% | +0.95% | View data |
| 2 | 2 Germany | 55.8 | 2023 | -2.62% | -3.96% | View data |
| 3 | 3 Spain | 22.7 | 2023 | +0.44% | -5.17% | View data |
| 4 | 4 Greece | 6.3 | 2023 | +3.28% | -4.9% | View data |
| 5 | 5 Ireland | 3.2 | 2023 | +3.23% | +0.64% | View data |
| 6 | 6 Estonia | 0.5 | 2023 | -16.67% | -8.97% | View data |
